
    
      The study consists of a 12-week double-blind, placebo-controlled treatment period.
      Participants will be randomized in a 1:1:1 ratio to PN-943 450 mg BID, PN-943 150 mg BID, or
      matching placebo BID.

      Participants who successfully complete the double-blind period may be eligible for an
      extended treatment period of 40 weeks duration.
    
  